Literature DB >> 8152808

Expression of two novel eph-related receptor protein tyrosine kinases in mammary gland development and carcinogenesis.

A C Andres1, H H Reid, G Zürcher, R J Blaschke, D Albrecht, A Ziemiecki.   

Abstract

To investigate the involvement of protein tyrosine kinases (PTKs) in the growth control of mammary epithelial cells, we have used PCR based cloning to identify PTKs expressed in a mouse mammary epithelial cell line. This approach led to the isolation of two receptor PTKs of the eph-related subfamily; myk-1, a novel member expressed predominantly in lung, heart and mammary gland and myk-2, a close relative of the human eck gene. Northern blot analysis of RNA from mouse mammary glands at different stages of development revealed that myk-1 and myk-2 expression is induced at puberty and differentially regulated during the estrus cycle. myk-1 and myk-2 expression was down-regulated during the pregnancy induced differentiation of the mammary gland. Over-expression of myk-1 and myk-2 was found in the undifferentiated and invasive mammary tumors of transgenic mice expressing the Ha-ras oncogene. In contrast, no elevated expression of either gene could be detected in the well differentiated and non-metastatic mammary tumors of c-myc expressing transgenic mice. These results indicate that myk-1 and myk-2 expression is induced during the proliferation of the mammary gland and down-regulated by its differentiation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8152808

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  41 in total

1.  An Eph receptor regulates integrin activity through R-Ras.

Authors:  J X Zou; B Wang; M S Kalo; A H Zisch; E B Pasquale; E Ruoslahti
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

Review 2.  Apoptosis in the estrous and menstrual cycles.

Authors:  A C Andres; R Strange
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-04       Impact factor: 2.673

3.  EphB6 crosslinking results in costimulation of T cells.

Authors:  Hongyu Luo; Guang Yu; Yulian Wu; Jiangping Wu
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

Review 4.  Differential regulation of EphA2 in normal and malignant cells.

Authors:  Jennifer Walker-Daniels; Angela R Hess; Mary J C Hendrix; Michael S Kinch
Journal:  Am J Pathol       Date:  2003-04       Impact factor: 4.307

Review 5.  Eph and ephrin signaling in mammary gland morphogenesis and cancer.

Authors:  Anne-Catherine Andres; Andrew Ziemiecki
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-10       Impact factor: 2.673

6.  EphB6-null mutation results in compromised T cell function.

Authors:  Hongyu Luo; Guang Yu; Johanne Tremblay; Jiangping Wu
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

7.  Expression of EphA2 and EphrinA-1 in vulvar carcinomas and its relation to prognosis.

Authors:  R Holm; S Knopp; Z Suo; C Tropè; J M Nesland
Journal:  J Clin Pathol       Date:  2006-12-08       Impact factor: 3.411

8.  Regulation of mammary gland branching morphogenesis by EphA2 receptor tyrosine kinase.

Authors:  David Vaught; Jin Chen; Dana M Brantley-Sieders
Journal:  Mol Biol Cell       Date:  2009-03-25       Impact factor: 4.138

9.  Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment.

Authors:  Masato Nishimura; Eun-Jung Jung; Maitri Y Shah; Chunhua Lu; Riccardo Spizzo; Masayoshi Shimizu; Hee Dong Han; Cristina Ivan; Simona Rossi; Xinna Zhang; Milena S Nicoloso; Sherry Y Wu; Maria Ines Almeida; Justin Bottsford-Miller; Chad V Pecot; Behrouz Zand; Koji Matsuo; Mian M Shahzad; Nicholas B Jennings; Cristian Rodriguez-Aguayo; Gabriel Lopez-Berestein; Anil K Sood; George A Calin
Journal:  Cancer Discov       Date:  2013-09-03       Impact factor: 39.397

Review 10.  The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.

Authors:  Jill Wykosky; Waldemar Debinski
Journal:  Mol Cancer Res       Date:  2008-12       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.